Clinical Report: Low-Dose Whole Body CT for Monitoring Smoldering Multiple Myeloma
Overview
This study evaluated the utility of whole-body low-dose CT (WBLDCT) in monitoring disease progression in 100 patients with smoldering multiple myeloma (SMM). WBLDCT enabled early detection of bone lesions indicative of progression to symptomatic multiple myeloma, facilitating timely initiation of treatment.
Background
Multiple myeloma (MM) is a hematological malignancy characterized by bone marrow infiltration of monoclonal plasma cells and bone disease. Smoldering multiple myeloma (SMM) is an asymptomatic intermediate stage with a 10% annual risk of progression to active MM. Imaging is critical for detecting bone lesions that define progression from SMM to MM, with whole-body low-dose CT emerging as a sensitive modality for identifying small osteolytic lesions. This study aimed to assess WBLDCT's role in early identification of bone disease progression in SMM patients.
Data Highlights
Parameter
Value
Number of patients
100
Median age at diagnosis
61 years (range 40–86)
Gender distribution
52 female / 48 male
Median number of WBLDCT exams per patient
2.5 (range 2–5)
Number of patients with 5 exams
3
Number of patients with 4 exams
9
Number of patients with 3 exams
24
Number of patients with 2 exams
64
Key Findings
WBLDCT detected well-defined osteolytic lesions ≥5 mm in trabecular bone, which are diagnostic of MM-related bone disease.
Low-dose CT protocols provided effective radiation doses comparable to conventional skeletal surveys, enabling safe serial imaging.
WBLDCT scans were performed at baseline, 1 year post-diagnosis, and annually thereafter, allowing longitudinal monitoring of bone disease progression.
Two experienced radiologists independently evaluated scans blinded to clinical data, ensuring objective assessment.
WBLDCT demonstrated higher sensitivity than conventional radiography in detecting small osteolytic lesions, critical for early diagnosis of progression from SMM to symptomatic MM.
Early identification of bone lesions by WBLDCT facilitated timely initiation of antimyeloma therapy in patients progressing to active disease.
Clinical Implications
Whole-body low-dose CT is a valuable imaging modality for monitoring patients with smoldering multiple myeloma, enabling early detection of bone lesions that signify progression to active disease. Its high sensitivity and low radiation exposure support its use in routine surveillance, guiding timely therapeutic decisions. Incorporation of WBLDCT into clinical protocols may improve patient outcomes by identifying progression before symptomatic complications arise.
Conclusion
WBLDCT is an effective, sensitive, and safe imaging technique for early detection of bone disease progression in smoldering multiple myeloma. Its use facilitates prompt diagnosis and treatment initiation, potentially improving clinical outcomes.
References
International Myeloma Working Group 2014 -- Diagnostic Criteria for Multiple Myeloma
Rajkumar 2011 -- Smoldering Multiple Myeloma: Clinical Features and Risk of Progression
Dimopoulos et al. 2015 -- Role of Imaging in Multiple Myeloma
Walker et al. 2018 -- Advances in Imaging for Myeloma Bone Disease
